8C34CD93-1AC0-4920-9E72-439EED0CF85D
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 40.30880420499343
- age_years
- 44
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.473
- TGF_BETA_SIGNALING+0.410
- INTERFERON_ALPHA_RESPONSE+0.387
- MYC_TARGETS_V1+0.355
- ADIPOGENESIS+0.352
- BILE_ACID_METABOLISM+0.325
- INTERFERON_GAMMA_RESPONSE+0.320
- NOTCH_SIGNALING+0.319
- INFLAMMATORY_RESPONSE+0.313
- MTORC1_SIGNALING+0.299
Top 10 suppressed
- KRAS_SIGNALING_DN-0.376
- SPERMATOGENESIS-0.210
- PANCREAS_BETA_CELLS-0.186
- MYOGENESIS-0.126
- APICAL_SURFACE-0.051
- ANGIOGENESIS-0.050
- APICAL_JUNCTION-0.050
- HEDGEHOG_SIGNALING+0.008
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.048
- ESTROGEN_RESPONSE_LATE+0.083
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 33060001-05C9-4751-AA58-F194207ACC08 | — | — | 0.963 |
| 2 | A061C2FD-B726-422D-9470-43249B49F5BD | — | — | 0.960 |
| 3 | 9ECB653A-A04F-457C-92FC-D13424511A47 | — | — | 0.956 |
| 4 | 6292335B-7CBB-45BE-AA2A-B39FFDA8768D | — | — | 0.941 |
| 5 | 8730AABF-0720-4754-82B0-722150A485B8 | — | — | 0.935 |
| 6 | B66ECF23-8CB2-4C95-8E3D-AA63A494F4A0 | — | — | 0.928 |
| 7 | 896B5096-D888-4DC3-9C70-152BDE083E26 | — | — | 0.926 |
| 8 | 928D2F99-A86B-47CA-A961-A8CAE7B44E78 | — | — | 0.926 |
| 9 | 95286AA4-B357-41FE-8051-3BD3EBE93885 | — | — | 0.921 |
| 10 | C9523C23-CF9B-4C33-A256-4106AD46729D | — | — | 0.919 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.473 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.410 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.387 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.355 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.352 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.325 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.320 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.319 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.313 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.299 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.298 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.295 | Inavolisib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| APOPTOSIS | 0.278 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.270 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.268 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.260 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.259 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.253 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.241 | Idelalisib | — uncovered |